REFERENCES
- De Biasio P, Prefumo F, Baffico M, Baldi M, Priolo M, Lerone M, Tomá P, Venturini PL. Sonographic and molecular diagnosis of thanatophoryc dysplasia type I at 18 weeks of gestation. Prenat Diagn 2000;20:835–7
- Schild RL, Hunt GH, Moore J, Davies H, Horwell DH. Antenatal sonographic diagnosis of thanotophoric dysplasia: a report of three cases and a review of the literature with special emphasis on differential diagnosis. Ultrasound Obstet Gynecol 1996;8:62–7
- Rousseau A, Saugier P, Le Merrer M, Munnich A, Delezoide AL, Maroteaux P, Bonaventure J, Narcy F, Sanak M. Stop codon FGFR3 mutations in thanatophoryc dwarfism type1. Nat Genet 1995;10:11–2.
- Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 1999;14:115–25.
- Yang Y, Li D. FGFR3 gene mutations in Chinese cases of thanatophoric dysplasia type 1. Fetal Diagn Ther 2009;26:90–2.
- Liu YN, Li R, Li DZ. Genotyping of the C742T mutation of the FGFR3 gene causing type 1 thanatophoric dysplasia by high-resolution melting analysis. J Matern Fetal Neonatal Med 2011;24:186–8.
- Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001;92:2555–61.
- Puri RD, Thakur S, Verma IC. Spectrum of severe skeletal dysplasias in North India. Indian J Pediatr 2007;74:995–1002.
- Vossen RH, Aten E, Roos A, den Dunnen JT. High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat 2009;30:860–66.